Press Release Dec 05 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release regarding a legal judgment. The Delhi High Court dismissed an appeal from FMC Corporation and upheld NATCO's position on its Chlorantraniliprole process. This ruling confirms that NATCO's process does not infringe FMC's patent.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Nov 16 2022
- Press Release Nov 12 2022
- Press Release Nov 09 2022
- Press Release Oct 21 2022
- Press Release Oct 04 2022
Later from NATCO Pharma
- Press Release Feb 04 2023
- Natco Pharma Limited Press Release Feb 13 2023
- Natco Pharma Limited Press Release Mar 01 2023
- Natco Pharma Limited Press Release Mar 10 2023
- Press Release May 29 2023
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma